Research paper
Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial
Study answer
What this study found
No significant difference in AVC progression over 24 months: MK-7 plus vitamin D changed AVC by 275 AU vs 292 AU in placebo (difference −17 AU; 95% CI −86 to 53; P=0.64). No significant differences in aortic valve area or peak jet velocity; progression of arterial calcification and need for valve surgery or cardiovascular events did not differ. dp-ucMGP decreased with MK-7 plus vitamin D (−212 pmol/L vs 45 pmol/L; P<0.001), indicating improved vitamin K status. The combination was safe and well tolerated. Conclusion: 2 years of MK-7 plus vitamin D does not slow AVC progression in elderly men…
- Study & population
- Multicenter randomized, double-blind, placebo-controlled trial at four Danish hospitals.
- Intervention
- Daily oral tablet containing 720 µg menaquinone-7 and 25 µg vitamin D for 24 months.
- Key limitation
- External validity limited to men aged 65-74 years with AVC >300 AU; 389 randomized from 660 eligible; 333 completed; potential underpower due to smaller-than-planned sample size and possible underdosing or insufficient duration; results may not apply to women.
View source
Open PDFOriginal abstract
Background: Menaquinone-7 (MK-7), also known as vitamin K2, is a cofactor for the carboxylation of proteins involved in the inhibition of arterial calcification and has been suggested to reduce the progression rate of aortic valve calcification (AVC)…